Literature DB >> 25103175

Does HIV antiretroviral therapy still need its backbone?

Manuel Battegay1, Luigia Elzi2.   

Abstract

Mesh:

Substances:

Year:  2014        PMID: 25103175     DOI: 10.1016/S0140-6736(14)61226-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  HIV viral kinetics and T cell dynamics in antiretroviral naïve persons starting an integrase strand transfer inhibitor and protease inhibitor regimen.

Authors:  Maile Y Karris; Sonia Jain; Tyler R C Day; Josué Pérez-Santiago; Miguel Goicoechea; Michael P Dubé; Xiaoying Sun; Celsa Spina; Eric S Daar; Richard H Haubrich; Sheldon Morris
Journal:  HIV Clin Trials       Date:  2017-01-30

2.  Effect of HIV infection and antiretroviral therapy on immune cellular functions.

Authors:  Marek Korencak; Morgan Byrne; Enrico Richter; Bruce T Schultz; Patrick Juszczak; Julie A Ake; Anuradha Ganesan; Jason F Okulicz; Merlin L Robb; Buena de Los Reyes; Sandra Winning; Joachim Fandrey; Timothy H Burgess; Stefan Esser; Nelson L Michael; Brian K Agan; Hendrik Streeck
Journal:  JCI Insight       Date:  2019-06-20

3.  Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue.

Authors:  Maile Y Karris; Sonia Jain; Vi Q Bowman; Gunter Rieg; Miguel Goicoechea; Michael P Dube; Shubha Kerkar; Carol Kemper; Catherine Diamond; Xiaoying Sun; Eric S Daar; Richard H Haubrich; Sheldon Morris
Journal:  J Acquir Immune Defic Syndr       Date:  2016-06-01       Impact factor: 3.731

4.  Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know?

Authors:  Marco Vitoria; Andrew M Hill; Nathan P Ford; Meg Doherty; Saye H Khoo; Anton L Pozniak
Journal:  J Int AIDS Soc       Date:  2016-02-02       Impact factor: 5.396

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.